Introduction:
Likarda, a biotechnology company, has entered into a licensing agreement with Cold Chain Technologies (CCT) to improve the logistics of cell therapy manufacturing. This collaboration will integrate Likarda’s hydrogel technology with CCT’s expertise in cold chain products and digital solutions to enhance the transportation and storage of biological materials and therapies.
- Likarda’s Core-Shell Spherification® (CSS®) technology allows cells and biological materials to be packaged on dry ice, eliminating the need for extremely low temperatures, such as liquid nitrogen (-196°C).
- Maintaining -196°C is challenging and expensive, but Likarda’s CSS hydrogels protect cells during transportation and storage, providing stability and preventing mechanical damage.
- The collaboration aims to set new standards for the storage and transportation of cell therapies, improving safety and reliability.
- By combining Likarda’s innovative technology with CCT’s packaging solutions, the partnership can revolutionize cryogenic shipments, making them more cost-effective and efficient.
- The agreement will expand the market presence and impact of both Likarda and CCT.
Conclusion:
The licensing agreement between Likarda and Cold Chain Technologies aims to enhance the logistics of cell therapy manufacturing by utilizing Likarda’s CSS technology and CCT’s expertise in cold chain products. This collaboration has the potential to revolutionize cryogenic shipments, making them more accessible and cost-effective, ultimately improving the safety and reliability of cell therapies.
